ProQR Therapeutics (NASDAQ:PRQR) Cut to “Sell” at StockNews.com

StockNews.com cut shares of ProQR Therapeutics (NASDAQ:PRQR) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

PRQR has been the topic of several other research reports. HC Wainwright reissued a buy rating and set a $5.00 target price on shares of ProQR Therapeutics in a research report on Friday, May 10th. Chardan Capital reissued a buy rating and issued a $2.50 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. Finally, Citigroup lifted their price target on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the stock a buy rating in a research note on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $3.38.

ProQR Therapeutics Stock Down 3.5 %

ProQR Therapeutics stock opened at $1.65 on Friday. ProQR Therapeutics has a 52-week low of $1.11 and a 52-week high of $3.29. The firm’s fifty day moving average is $1.90 and its 200 day moving average is $2.05. The company has a market cap of $134.24 million, a price-to-earnings ratio of -4.46 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The firm had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.31 million. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. On average, equities research analysts anticipate that ProQR Therapeutics will post -0.37 earnings per share for the current fiscal year.

Institutional Trading of ProQR Therapeutics

A number of large investors have recently made changes to their positions in PRQR. Ikarian Capital LLC increased its stake in ProQR Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after buying an additional 10,958 shares during the period. BNP Paribas Financial Markets increased its position in shares of ProQR Therapeutics by 120.1% during the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 19,100 shares during the period. RFG Advisory LLC bought a new stake in shares of ProQR Therapeutics during the first quarter valued at approximately $73,000. Acadian Asset Management LLC purchased a new stake in shares of ProQR Therapeutics in the first quarter valued at approximately $56,000. Finally, EP Wealth Advisors LLC bought a new position in ProQR Therapeutics in the first quarter worth approximately $26,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).